(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 November 2022 (03.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/232504 A1

(51) International Patent Classification:
A61K 31/58 (2006.01) *A61P 25/24* (2006.01)
A61P 25/22 (2006.01) *A61K 45/06* (2006.01)

(21) International Application Number:
PCT/US2022/026920

(22) International Filing Date:
29 April 2022 (29.04.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/181,743	29 April 2021 (29.04.2021)	US
63/197,025	04 June 2021 (04.06.2021)	US
63/210,810	15 June 2021 (15.06.2021)	US
63/239,096	31 August 2021 (31.08.2021)	US
63/285,812	03 December 2021 (03.12.2021)	US
63/289,506	14 December 2021 (14.12.2021)	US
63/289,520	14 December 2021 (14.12.2021)	US
63/298,601	11 January 2022 (11.01.2022)	US

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US]; 215 First Street, Cambridge, MA 02142 (US).

(72) Inventors: **LASSER, Robert, Alfonso**; 215 First Street, Cambridge, MA 02142 (US). **DOHERTY, James**; 215 First Street, Cambridge, MA 02142 (US). **JONAS, Jeffrey, Martin**; 215 First Street, Cambridge, MA 02142 (US). **KANES, Stephen, Jay**; 215 First Street, Cambridge, MA 02142 (US). **GUNDUZ-BRUCE, Handan**; 215 First Street, Cambridge, MA 02142 (US). **COLQUHOUN, Helen, Anne**; 215 First Street, Cambridge, MA 02142 (US). **ARNOLD, Ryan**; 215 First Street, Cambridge, MA 02142 (US). **BONTHAPALLY, Vijayveer**; 215 First Street, Cambridge, MA 02142 (US). **DUNBAR, Joi, Lisa**; 215 First Street, Cambridge, MA 02142 (US). **ADIWIJAYA, Bambang, Senoaji**; 215 First Street, Cambridge, MA 02142 (US).


(74) Agent: **DOYLE, Kathryn, D.**; Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: 19-NOR C3,3-DISUBSTITUTED C21 -N-PYRAZOLYL STEROID FOR USE IN TREATING MAJOR DEPRESSIVE DISORDER AND POSTPARTUM DEPRESSION



Compound **(1)**.

(57) Abstract: The present disclosure relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof. The disclosure also relates to Compound (1) or a pharmaceutically acceptable salt thereof, for use in methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof.

WO 2022/232504 A1